The Veterinary Record Link to Vetlife website
HOME CURRENT ISSUE TABLE OF CONTENTS ARCHIVE SEARCH SUBSCRIPTIONS JOBS FEEDBACK HELP
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Stewart, R. J. E.
Right arrow Articles by Den Otter, W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Stewart, R. J. E.
Right arrow Articles by Den Otter, W.
The Veterinary Record 159:668-672 (2006)
© 2006 British Veterinary Association

Papers and Articles

Treatment of ocular squamous cell carcinomas in cattle with interleukin-2

R. J. E. Stewart, BVSc, MVSc1, F. W. G. Hill, PhD, DSc, MRCVS2, A. Masztalerz, MSc, PhD3, J. J. L. Jacobs, MSc, PhD5, J. W. Koten, MD, PhD4 and W. Den Otter, MSc, PhD4

1 Faculty of Veterinary Science, University of Zimbabwe, PO Box MP167, Mount Pleasant, Harare, Zimbabwe
2 Faculty of Medicine, University of Zimbabwe, PO Box MP167, Mount Pleasant, Harare, Zimbabwe
3 Department of Cell Biology and Histology, Faculty of Veterinary Medicine, Utrecht University PO Box 80.158, 3508 TD Utrecht, The Netherlands
4 Department of Pathobiology, Faculty of Veterinary Medicine, Utrecht University PO Box 80.158, 3508 TD Utrecht, The Netherlands
5 AmCOGG Research Institute Amsterdam Centre for Health and Health Care Research, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands

In total, 174 bovine ocular squamous cell carcinomas of varying sizes (20 to 2800 mm2 in area) were treated daily with peritumoural injections of solvent, or solvent containing 5000 U, 20,000 U, 200,000 U, 500,000 U, 1 million U or 2 million U interleukin-2 (IL-2) for 10 days. The tumours were measured and clinically staged before treatment and at one, three, four, nine and 20 months after treatment. After 20 months, 14 per cent of the tumours treated with the solvent had regressed completely, a significantly smaller proportion than the 55 per cent treated with 5000 U IL-2, 52 per cent treated with 20,000 U IL-2, 58 per cent treated with 200,000 U IL-2, 50 per cent treated with 500,000 U IL-2, 69 per cent of tumours treated with 1 million U IL-2, 52 per cent treated with 2 million U IL-2. The tumours on the third eyelid and limbus were the most responsive.






HOME CURRENT ISSUE TABLE OF CONTENTS ARCHIVE SEARCH SUBSCRIPTIONS JOBS FEEDBACK HELP
Copyright © 2006 British Veterinary Association